Exact Mass: 566.2152
Exact Mass Matches: 566.2152
Found 500 metabolites which its exact mass value is equals to given mass value 566.2152
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N-[6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
PA(2:0/6 keto-PGF1alpha)
PA(2:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/6 keto-PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(6 keto-PGF1alpha/2:0)
PA(6 keto-PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/2:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/TXB2)
PA(2:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/TXB2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(TXB2/2:0)
PA(TXB2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/2:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
4-Methoxy-3,3,5-trihydroxystilbene 3-O-beta-D-(2-O-p-coumaryl)-glucopyranoside
methyl (4S,5E,6S)-5-ethylidene-4-[2-oxo-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
(5S,6R,7R,8S)-2-(2-Phenylethyl)-5,6,7-tri-hydroxy-5,6,7,8-tetrahydro-8-[2-(2-phenylethyl)chromonyl-6-oxy]chromone (AH13)|(5S,6R,7R,8S)-2-(2-phenylethyl)-5,6,7-trihydroxy-5,6,7,8-tetrahydro-8-<2-(2-phenylethyl)chromonyl-6-oxy>chromone|(5S,6R,7R,8S)-2-(2-phenylethyl)-5,6,7-trihydroxy-5,6,7,8-tetrahydro-8-[2-(2-phenylethyl)chromonyl-6-oxy]chromone|AH13
(1aR,1bS,2S,5aS,6S,6aS)-2-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-5-carboxylic acid methyl ester|6-O-beta-D-glucopyranosylphlorigidoside C
(5S,6S,7S,8R)-2-(2-phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-<2-(2-phenylethyl)chromonyl-6-oxy>chromone|(5S,6S,7S,8R)-2-(2-phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-[2-(2-phenylethyl)chromonyl-6-oxy]chromone|(5S,6S,7S,8R)-2-(2-Phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-[2-(2-phenylethyl)chromonyl-6-oxy]chromone (AH14)|AH10
(1R,2S,4S,5S,6R,7S,8S,9R,10S)-1-acetoxy-9-benzoyloxy-8-trans-cinnamoyloxy-2,4,6-trihydroxydihydro-beta-agarofuran
(rel)-(1R,4aS,8S,8aS)-8-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-4,4a,8,8a-tetrahydro-1-methyl-3-oxo-1H,3H-pyrano[3,4-c]pyran-5-carboxylic acid methyl ester|lamiuamplexoside B
(2R,3S,4S)-2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-4-[(4-hydroxy-3-methoxyphenyl)methyl]tetrahydrofuran 3-{[(2R)-2-carbomethoxy-2-hydroxy]ethyl}benzoate|hyosmin
(l(-)-tyrosyl)=>glutaminyl=>glutaminyl=>-glutamic acid|(l(-)-Tyrosyl)=>glutaminyl=>glutaminyl=>-glutaminsaeure
monodictyochromone A
A chromanone isolated from the marine derived fungus Monodictys putredinis and exhibits inhibitory activity against P450.
10-(6-O-trans-sinapoyl-beta-D-glucopyranosyl)gardendiol|11-(6-O-trans-sinapoyl-beta-glucopyranosyl)gardendiol
12-O-butenoyl-5-hydroxy-6,7-epoxy-resiniferonol-9,13,14-orthobenzoate
4-methoxy-9,10-dihydrophenanthrene-2,7-di-O-beta-D-glucopyranoside
(2E)-1-{2,4-dihydroxy-6-methoxy-3-[(2R,4S,6S)-tetrahydro-2-(4-hydroxyphenyl)-6-(2-phenylethyl)-2H-pyran-4-yl]phenyl}-3-(4-hydroxyphenyl)prop-2-en-1-one|Katsumain D
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-4-[(2S)-2-hydroxy-4-(4-hydroxyphenyl)butyl]-2-(4-hydroxyphenyl)-7-methoxy-2H-1-benzopyran-6-yl}-3-phenylprop-2-en-1-one|katsumain E
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4-[(2S)-2-hydroxy-4-phenylbutyl]-7-methoxy-2H-1-benzopyran-6-yl}-3-(4-hydroxyphenyl)prop-2-en-1-one|katsumain G
(+)-lyoniresinol-3alpha-O-alpha-L-rhamonopyranoside
E-3-[3-(benzoyloxymethyl)-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-2,3-dihydrobenzo[b]furan-5-yl]prop-2-enyl benzoate
(aS)-(5R,6S,7R,8R)-8-benozyloxy-5,6,7,8-tetrahydro-1,5-dihydroxy-3,12-dihydroxy-1,2,10,11-tetramethoxy-6,7-dimethyldibenzo[a,c]cycloocten-5-yl acetate|kadsuphilin I
10-(6-O-trans-sinapoyl-beta-glucopyranosyl)gardendiol|11-(6-O-trans-sinapoyl-beta-D-glucopyranosyl)gardendiol
(8R*,7S*,8R*)-5,5-dimethoxy-7-oxolariciresinol 9-O-beta-D-xylopyranoside
5-methylresveratrol-3,4-O-beta-D-diglucopyranoside
monodictyochromone B
A chromanone isolated from the marine derived fungus Monodictys putredinis and exhibits inhibitory activity against P450.
Asn Tyr Arg Asp
Asn Tyr Asp Arg
4-[4-(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy-2-methoxy-3,5,6-trimethylbenzoyl]oxy-2-methoxy-3,5,6-trimethylbenzoic acid
C23H34O16_beta-D-Glucopyranose, 1-[2-[(2S,3E,4S)-3-ethylidene-2-(beta-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetate]
methyl (4S,5E,6S)-5-ethylidene-4-[2-oxo-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate_major
methyl (4S,5E,6S)-5-ethylidene-4-[2-oxo-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate_98.3\\%
Ala Gln Trp Tyr
Ala Gln Tyr Trp
Ala Trp Gln Tyr
Ala Trp Tyr Gln
Ala Tyr Gln Trp
Ala Tyr Trp Gln
Cys Cys Arg Trp
Cys Cys Trp Arg
Cys Lys Met Trp
Cys Lys Trp Met
Cys Met Lys Trp
Cys Met Gln Trp
Cys Met Trp Lys
Cys Met Trp Gln
Cys Gln Met Trp
Cys Gln Trp Met
Cys Arg Cys Trp
Cys Arg Trp Cys
Cys Trp Cys Arg
Cys Trp Lys Met
Cys Trp Met Lys
Cys Trp Met Gln
Cys Trp Gln Met
Cys Trp Arg Cys
Asp Asn Arg Tyr
Asp Asn Tyr Arg
Asp Arg Asn Tyr
Asp Arg Tyr Asn
Asp Tyr Asn Arg
Asp Tyr Arg Asn
Glu Gln Gln Tyr
Glu Gln Tyr Gln
Glu Tyr Gln Gln
Phe His Thr Tyr
Phe His Tyr Thr
Phe Asn Thr Trp
Phe Asn Trp Thr
Phe Gln Ser Trp
Phe Gln Trp Ser
Phe Ser Gln Trp
Phe Ser Trp Gln
Phe Thr His Tyr
Phe Thr Asn Trp
Phe Thr Trp Asn
Phe Thr Tyr His
Phe Trp Asn Thr
Phe Trp Gln Ser
Phe Trp Ser Gln
Phe Trp Thr Asn
Phe Tyr His Thr
Phe Tyr Thr His
His Phe Thr Tyr
His Phe Tyr Thr
His His His His
His Thr Phe Tyr
His Thr Tyr Phe
His Tyr Phe Thr
His Tyr Thr Phe
Lys Cys Met Trp
Lys Cys Trp Met
Lys Met Cys Trp
Lys Met Trp Cys
Lys Trp Cys Met
Lys Trp Met Cys
Met Cys Lys Trp
Met Cys Gln Trp
Met Cys Trp Lys
Met Cys Trp Gln
Met Lys Cys Trp
Met Lys Trp Cys
Met Gln Cys Trp
Met Gln Trp Cys
Met Trp Cys Lys
Met Trp Cys Gln
Met Trp Lys Cys
Met Trp Gln Cys
Asn Asp Arg Tyr
Asn Asp Tyr Arg
Asn Phe Thr Trp
Asn Phe Trp Thr
Asn Arg Asp Tyr
Asn Arg Tyr Asp
Asn Thr Phe Trp
Asn Thr Trp Phe
Asn Trp Phe Thr
Asn Trp Thr Phe
Gln Ala Trp Tyr
Gln Ala Tyr Trp
Gln Cys Met Trp
Gln Cys Trp Met
Gln Glu Gln Tyr
Gln Glu Tyr Gln
Gln Phe Ser Trp
Gln Phe Trp Ser
Gln Met Cys Trp
Gln Met Trp Cys
Gln Gln Glu Tyr
Gln Gln Tyr Glu
Gln Ser Phe Trp
Gln Ser Trp Phe
Gln Trp Ala Tyr
Gln Trp Cys Met
Gln Trp Phe Ser
Gln Trp Met Cys
Gln Trp Ser Phe
Gln Trp Tyr Ala
Gln Tyr Ala Trp
Gln Tyr Glu Gln
Gln Tyr Gln Glu
Gln Tyr Trp Ala
Arg Cys Cys Trp
Arg Cys Trp Cys
Arg Asp Asn Tyr
Arg Asp Tyr Asn
Arg Asn Asp Tyr
Arg Asn Tyr Asp
Arg Trp Cys Cys
Arg Tyr Asp Asn
Arg Tyr Asn Asp
Ser Phe Gln Trp
Ser Phe Trp Gln
Ser Gln Phe Trp
Ser Gln Trp Phe
Ser Trp Phe Gln
Ser Trp Gln Phe
Thr Phe His Tyr
Thr Phe Asn Trp
Thr Phe Trp Asn
Thr Phe Tyr His
Thr His Phe Tyr
Thr His Tyr Phe
Thr Asn Phe Trp
Thr Asn Trp Phe
Thr Trp Phe Asn
Thr Trp Asn Phe
Thr Tyr Phe His
Thr Tyr His Phe
Trp Ala Gln Tyr
Trp Ala Tyr Gln
Trp Cys Cys Arg
Trp Cys Lys Met
Trp Cys Met Lys
Trp Cys Met Gln
Trp Cys Gln Met
Trp Cys Arg Cys
Trp Phe Asn Thr
Trp Phe Gln Ser
Trp Phe Ser Gln
Trp Phe Thr Asn
Trp Lys Cys Met
Trp Lys Met Cys
Trp Met Cys Lys
Trp Met Cys Gln
Trp Met Lys Cys
Trp Met Gln Cys
Trp Asn Phe Thr
Trp Asn Thr Phe
Trp Gln Ala Tyr
Trp Gln Cys Met
Trp Gln Phe Ser
Trp Gln Met Cys
Trp Gln Ser Phe
Trp Gln Tyr Ala
Trp Arg Cys Cys
Trp Ser Phe Gln
Trp Ser Gln Phe
Trp Thr Phe Asn
Trp Thr Asn Phe
Trp Tyr Ala Gln
Trp Tyr Gln Ala
Tyr Ala Gln Trp
Tyr Ala Trp Gln
Tyr Asp Asn Arg
Tyr Asp Arg Asn
Tyr Glu Gln Gln
Tyr Phe His Thr
Tyr Phe Thr His
Tyr His Phe Thr
Tyr His Thr Phe
Tyr Asn Asp Arg
Tyr Asn Arg Asp
Tyr Gln Ala Trp
Tyr Gln Glu Gln
Tyr Gln Gln Glu
Tyr Gln Trp Ala
Tyr Arg Asp Asn
Tyr Arg Asn Asp
Tyr Thr Phe His
Tyr Thr His Phe
Tyr Trp Ala Gln
Tyr Trp Gln Ala
Cediranib maleate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents
2-[(1E,3E)-5-(3,3-DIMETHYL-1-PROPYL-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)-1,3-PENTADIENYL]-3,3-DIMETHYL-1-PROPYL-3H-INDOLIUM IODIDE
ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride
1-{[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazol-1-YL]carbonyl}piperazine
(4aS,5S,12aS)-2-carbamoyl-6-[(2E)-3,7-dimethylocta-2,6-dienyl]-4a,5,10,11,12a-pentahydroxy-8-methoxy-3,12-dioxo-4,5-dihydrotetracen-1-olate
Dehydrodiconiferyl dibenzoate
A lignan that is 2,3-dihydro-1-benzofuran substituted by a (benzoyloxy)methyl group at position 3, a 4-hydroxy-3-methoxyphenyl group at position 2, a methoxy group at position 7 and a 3-(benzoyloxy)prop-1-en-1-yl group at position 5. It is isolated as a racemate from Euterpe precatoria and exhibits antiplasmodial activity.
Meclorisone dibutyrate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
N-[3-(dimethylamino)propyl]-N-(4-ethoxy-1,3-benzothiazol-2-yl)-4-[methyl-(phenylmethyl)sulfamoyl]benzamide
4-fluoro-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
1-[[(2S,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
4-fluoro-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
1-[[(2S,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
4-fluoro-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide
1-[[(2R,3R)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3R)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
6-[[10-Butanoyl-3-hydroxy-6-(2-hydroxypropyl)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-5-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
3,4,5-Trihydroxy-6-[[3-hydroxy-10-(3-hydroxybutanoyl)-2,2-dimethyl-8-oxo-6-propyl-3,4-dihydropyrano[3,2-g]chromen-5-yl]oxy]oxane-2-carboxylic acid
5-[(E)-2-[(2S,3R,4S)-5-carboxy-3-ethenyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-4-yl]ethenyl]-1-(3-carboxypropyl)pyridin-1-ium-3-carboxylic acid
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
({20-chloro-13,19,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl}oxy)methanimidic acid
(9s,9's)-2,2',4,4',5,5'-hexahydroxy-7,7'-dipropyl-9h,9'h-[9,9'-bianthracene]-10,10'-dione
(4r,5r)-1,5-bis(3,4-dimethoxyphenyl)-5-methoxy-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentan-1-one
methyl (1s,2r,4s,5s,6s,10s)-5-hydroxy-2-methyl-10-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,9-dioxatricyclo[4.4.0.0²,⁴]dec-7-ene-7-carboxylate
[3,4-dihydroxy-5-({3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl}methoxy)oxolan-3-yl]methyl 4-methoxybenzoate
1-(1r,13r)-7,7-dimethyl-18-(3-methylbut-2-en-1-yl)-8,12,20-trioxapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁴,¹⁹]henicosa-2,4(9),5,10,14,16,18-heptaen-17-yl 2-ethyl phthalate
(2e)-3-[(2r,3s)-3-[(benzoyloxy)methyl]-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]prop-2-en-1-yl benzoate
methyl (1r,4as,6s,8s,8ar)-6-methoxy-8-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2z)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}methyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,8h,8ah-pyrano[3,4-c]pyran-4-carboxylate
34,38-dimethyl-8,10,15,22,27,29-hexaoxa-34,38-diazaundecacyclo[19.11.3.3⁴,¹⁶.2³,¹⁷.0¹,²¹.0²,¹⁸.0⁴,¹⁶.0⁵,¹³.0⁷,¹¹.0²⁴,³².0²⁶,³⁰]tetraconta-5,7(11),12,19,24,26(30),31,36-octaene
(1r,2r,4r,9r,10r,13r,14s,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadec-5-en-17-yl (2e)-2-methylbut-2-enoate
6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-14-phenyl-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl but-2-enoate
2-{[4-(4-hydroxy-3,5-dimethoxyphenyl)-1-(4-hydroxy-3-methoxyphenyl)-tetrahydro-1h-furo[3,4-c]furan-3a-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
5'-(furan-3-yl)-8-methyl-2'-oxo-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[naphtho[1,8a-c]furan-7,3'-oxolan]-10-yl acetate
(1s,2r,3s,4r,7s,8z,10r,12s,13r,14s)-10,12,14-tris(acetyloxy)-3-hydroxy-9-(hydroxymethyl)-4,13,17-trimethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,16-dien-2-yl acetate
2-(2-phenylethyl)-6-{[(5s,6s,7r,8s)-6,7,8-trihydroxy-4-oxo-2-(2-phenylethyl)-5,6,7,8-tetrahydrochromen-5-yl]oxy}chromen-4-one
5-hydroxy-6-[5-hydroxy-2-methyl-2-(3-methyl-5-oxooxolan-2-yl)-4-oxo-3h-1-benzopyran-6-yl]-2-(3-hydroxy-5-oxooxolan-2-yl)-2,7-dimethyl-3h-1-benzopyran-4-one
3,6,11-tris(acetyloxy)-2,8-dihydroxy-1,5,15-trimethyl-9-methylidene-14-oxo-16-oxatetracyclo[10.5.0.0²,¹⁵.0⁵,¹⁰]heptadecan-4-yl acetate
7-methyl 4-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4as,7s,7as)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4,7-dicarboxylate
(3r)-3,8-dihydroxy-9-[(2r,4r,5r,6r)-5-hydroxy-4-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(1's,2r,2's,3's,4'r,7's,8'z,10'r,12's,13'r,14's)-2',10',14'-tris(acetyloxy)-3'-hydroxy-4',9',13'-trimethyl-5'-oxo-6'-oxaspiro[oxirane-2,17'-tricyclo[11.4.0.0³,⁷]heptadecan]-8'-en-12'-yl acetate
2-(4-hydroxyphenyl)ethyl-1-o-β-d-[5-o-(4-methoxybenzoyl)]-apiofuranosyl-(1→6)-β-d-glucopyranoside
{"Ingredient_id": "HBIN004418","Ingredient_name": "2-(4-hydroxyphenyl)ethyl-1-o-\u03b2-d-[5-o-(4-methoxybenzoyl)]-apiofuranosyl-(1\u21926)-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C27H34O13","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10605","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}